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Abstract 
The purpose of this study was to investigate the effects of Montmorency tart cherry juice 
(MC) on nitric oxide (NO) biomarkers, vascular function and exercise performance. In a 
randomized, double blind, placebo (PLA) – controlled, crossover study, 10 trained cyclists 
(mean ± SD; V̇O2peak 59.0 ± 7.0 ml/kg/min) acutely ingested 30 mL of either MC or PLA 
following dietary restrictions of polyphenol-rich compounds, and completed 6 min moderate- 
and severe-intensity cycling bouts 1.5 h post ingestion on two occasions for each 
experimental condition.  The severe-intensity cycling test was continued to exhaustion on one 
occasion and immediately followed by a 60 s all-out sprint on the other occasion.  Blood 
pressure, pulse wave measures, tissue oxygenation index and plasma nitrite concentration 
were assessed pre and 1.5 h post ingestion.  Time to exhaustion was not different between 
conditions (P > 0.05), but peak power over the first 20 s (363 ± 42 vs. 330 ± 26 W) and total 
work completed during the 60 s all-out sprint (21 ± 3 vs. 19 ± 3 kJ) were 10% higher in the 
MC trial compared to the PLA trial (P < 0.05). Systolic blood pressure was 5 ± 2 mmHg 
lower 1.5 h post MC supplementation compared to PLA supplementation (P < 0.05).  There 
were no differences in pulse wave measures, plasma nitrite concentration or tissue 
oxygenation between the MC and PLA trials (P > 0.05). These results suggest that acute 
supplementation with MC can lower blood pressure and improve some aspects of exercise 
performance, specifically end-sprint performance, in trained cyclists.   
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Introduction  1 
Montmorency tart cherries (MC) are a rich source of polyphenols 1-3 including the flavonoids 2 
isorhamnetin, kaempferol, quercetin, catechin and anthocyanins 4,5.  It has been well 3 
documented that these plant compounds are associated with beneficial anti-inflammatory 6, 4 
antioxidant 7 (AOX), immunomodulatory and vasodilatory properties 8.  Previous studies 5 
demonstrated the positive effects of MC concentrate on indices of cardiovascular function 6 
that included increased cell migration 9, cerebral blood flow 10 and reduced systolic blood 7 
pressure at rest10,11.  These effects might be mediated, in part by the ability of polyphenols to 8 
facilitate endothelial nitric oxide synthase (eNOS) phosphorylation, thereby increasing 9 
endogenous nitric oxide (NO) production 12. However, an increase in NO biomarkers has not 10 
been demonstrated with polyphenol-rich MC.   11 
An increased muscle blood flow may increase the oxidative energy contribution over the 12 
initial stages of exercise and reduce the development of the V̇O2 slow component (a 13 
progressive increase in O2 uptake (V̇O2) as high intensity exercise is continued) 13.  14 
Supplementation with MC might have the potential to improve aspects of the dynamic V̇O2 15 
response during exercise by enhancing endothelial function and, hence, have a positive effect 16 
on performance.  In addition, cyanidin-3-glucoside, an anthocyanin found in abundance in 17 
MC concentrate 3, has been shown to increase endothelial NO synthase (eNOS) expression 18 
and decrease inducible NO synthase (iNOS) expression 14. Such changes in the balance 19 
between eNOS and iNOS expression/activity would favour the bioavailability of the 20 
vasoactive NO. Therefore, if MC does increase NO bioavailability, it is possible that muscle 21 
O2 delivery and/or its intramuscular distribution might be enhanced which, in turn, could be 22 
advantageous at the onset of exercise and during maximal exercise.  Further to these 23 
mechanisms, other compounds in tart Montmorency cherries such as quercetin (which is 24 
reported to be present in MC 15) binds and antagonises the adenosine receptor, which could 25 
improve performance in a caffeine-like manner 16. Similarly, MC concentrate is rich in AOX 26 
compounds that also have the potential to augment performance 17.  27 
Despite the potential vasodilatory and AOX properties of tart cherries, only two studies have 28 
investigated the effect of tart Montmorency cherry supplementation on continuous exercise 29 
capacity and performance.  Clifford and colleagues 18 investigated the influence of different 30 
sources of polyphenols on sub-maximal cycling and time trial performance.  Supplementation 31 
with 200 mg of dried Montmorency cherry capsules for three days, did not improve cycling 32 
time trial performance, heart rate, respiratory exchange ratio, gross mechanical efficiency, 33 
oxygen consumption, or blood [lactate] in moderately trained cyclists (V̇O2peak 52.4 ± 8.7 34 
ml/kg/min). In contrast, when participants were supplemented with powdered tart cherry 35 
capsules for 10 days, half-marathon completion times were 13% faster than their placebo 36 
counterparts19, although the mechanism for this improvement remains unclear. It should be 37 
noted that the actual race pace was slower compared to the projected race pace in both groups, 38 
but the difference tended to be smaller in the tart cherry group compared to the placebo group.  39 
Furthermore, the authors of this study acknowledged that the participants were matched 40 
based on average reported race pace, and therefore there might be some variability amongst 41 
groups. As a result, further studies with a strong study design are needed to evaluate if 42 
supplementation with tart cherries can provide benefits to exercise performance.  43 
Similar performance-enhancing findings have been reported in other studies where 44 
polyphenolic content of a fruit-derived supplement is similar to tart cherries 20,21. Kang and 45 
colleagues20 reported that oligomerized lychee fruit extract increased the anaerobic threshold 46 
by 7.4%. More recently, Cook et al. 21 reported that following a seven-day intake of New 47 
Zealand blackcurrant extract, there was an improvement in cycling time-trial performance by 48 
2.4%. The authors speculated that this improvement might have been the result of improved 49 
endothelial function and increased peripheral blood flow. Conversely, in another study 22, 50 
supplementation with a polyphenol antioxidant for 1 week failed to improve exercise 51 
performance, cardiovascular function, and thermoregulatory control in well-trained cyclists. 52 
The lack of improvement in exercise performance may be related to the training status of the 53 
subjects, exercise modality, and/or the experimental conditions under which performance was 54 
assessed. 55 
Although the potential beneficial role of MC in expediting exercise recovery has been 56 
unequivocally demonstrated 23,24, it is still unclear whether acute MC supplementation can 57 
improve endurance exercise performance.  Given that most polyphenol compounds are either 58 
absorbed or excreted quickly 9,10,25, longer-term (10-day) supplementation periods 19 may not 59 
be necessary to observe improvements in performance.   Furthermore, the potential 60 
mechanisms that might underpin any ergogenic effects of MC consumption are yet to be fully 61 
resolved. Therefore, the purpose of this study was to investigate the effects of acute MC 62 
supplementation on plasma NO2- concentration ([NO2-]), a sensitive marker of NOS activity 63 
26, as well as blood pressure, V̇O2 kinetics, muscle oxygenation and exercise performance 64 
using a double-blind, cross-over experimental study design. We also used near-infrared 65 
spectroscopy to provide insight into the matching between skeletal muscle O2 delivery and 66 
utilisation 27 and, therefore the potential underlying mechanisms for improvement in V̇O2 67 
kinetics or exercise performance following MC supplementation.   68 
Methods 69 
Participants 70 
Eleven trained male cyclists volunteered to take part in the study, but one participant 71 
withdrew after the second study day (mean ± SD age; 28 ± 7 years, stature 1.83 ± 0.06 m, 72 
body mass 78.0 ± 8.5 kg and V̇O2peak 59.0 ± 7.0 ml/kg/min). Exclusion criteria for the study 73 
were: V̇O2peak < 50 ml/kg/min (determined on visit 1), smoking, food allergy (as discussed 74 
with research team), history of gastrointestinal, renal or cardiovascular disease and current 75 
use of any food supplementations. All participants provided written, informed consent prior 76 
to the commencement of the study.  For 24 h prior to and for each of the testing days, 77 
participants were asked to avoid strenuous exercise, alcohol, caffeine, nutritional supplements 78 
and any anti-inflammatory drugs. Participants were instructed to follow a low phenolic diet 79 
for 24 h prior to each arm of the trial by avoiding fruits, vegetables, tea, coffee, alcohol, 80 
chocolate, cereals, wholemeal bread, grains and spices and were asked to refrain from 81 
strenuous exercise.  Compliance with the dietary restrictions was monitored with a 82 
standardised, self-reported dietary record.  Participants were asked to arrive at the laboratory 83 
in a rested and fully hydrated state, ≥10 h postprandial.  All tests were performed at the same 84 
time of day.  The study was conducted in accordance with the Helsinki Declaration and 85 
ratified by the University’s Research Ethics Committee. 86 
Study Design 87 
Participants were required to report to the laboratory on five occasions over a 4-5 week 88 
period to complete the experimental testing (1 familiarization / V̇O2peak visit and 4 89 
experimental visits).  On the first visit to the laboratory, participants completed a ramp 90 
incremental exercise test for determination of the gas exchange threshold (GET) and peak 91 
V̇O2 (V̇O2peak).  Participants were also familiarized with the two exercise performance tests 92 
employed in the study on this visit to avoid any order effect on the performance results as a 93 
consequence of a potential “learning effect”.  Participants then returned to the laboratory on 94 
visits 2, 3, 4 and 5 to complete the experimental testing (MC × 2 trials, PLA × 2 trials).  95 
During these tests, resting blood pressure, arterial stiffness, pulmonary V̇O2 kinetics during 96 
moderate and severe intensity exercise, muscle oxygenation, and exercise performance were 97 
assessed, and venous blood samples were obtained.  The MC concentrate and placebo (PLA) 98 
drinks were administered in a randomized order as part of a double–blind, crossover 99 
experimental design.  Each supplementation day was separated by at least 3 days, but no 100 
more than 7 days. 101 
Incremental Test.   102 
During the first laboratory visit, participants completed a ramp incremental cycle test on an 103 
electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands).  104 
Initially, participants performed 3 min of baseline cycling at 0 W, after which the work rate 105 
was increased by 30 W/min until the limit of tolerance.  The participants cycled at a self-106 
selected pedal rate, which, along with saddle and handle bar heights and configuration, was 107 
recorded and reproduced in subsequent tests.  Breath-by-breath pulmonary gas exchange data 108 
were collected continuously during the incremental tests and averaged over consecutive 10 s 109 
periods.  The V̇O2peak was taken as the highest 30 s rolling mean value attained prior to the 110 
participant’s volitional exhaustion in the test.  The GET was determined as 1) the first 111 
disproportionate increase in CO2 production (V̇CO2) from visual inspection of individual 112 
plots of V̇CO2 and V̇O2, and an increase in expired ventilation V̇E/ V̇O2 with no increase in 113 
V̇E/ V̇CO2.  The work rate that would require 90% of the GET (moderate – intensity exercise) 114 
and 70% Δ (GET + 70% of the difference between the work rate at the GET and V̇O2peak; 115 
severe intensity exercise) were calculated.  The V̇O2 peak attained in the ramp incremental 116 
test was 4.56 ± 0.3 l/min, which equated to a relative V̇O2 peak of 59.0 ± 7.0 ml·kg−1·min−1. 117 
The work rates that corresponded to 90% GET and 70%Δ were 121 ± 19 and 303 ± 28 W, 118 
respectively.  The mean response time (MRT) for V̇O2 during ramp exercise was taken into 119 
account, specifically two-thirds of the ramp rate was deducted from the work rate at GET and 120 
peak V̇O2 (i.e., 20W 28).   121 
 122 
Following the incremental test and a 45-minute rest, participants were familiarized with the 123 
exercise tests.  Participants completed a moderate- intensity and severe-intensity, step test 124 
finishing with an all-out sprint followed (after a 30-minute passive recovery period) by a 125 
severe-intensity constant-work-rate step exercise test to the limit of tolerance.  126 
Experimental tests.  127 
On all subsequent visits, participants were required to rest in a seated position for 10 min in 128 
an isolated room.  Thereafter, baseline blood pressure of the brachial artery was measured 129 
using an automated sphygmomanometer (M10-IT Omron Healthcare, UK) according to 130 
British Hypertension Society guidelines.  Additionally, pulse wave velocity and pulse wave 131 
analysis were determined by using Arterial Tonometry (SphygmoCor CPV system, ScanMed 132 
Medical, UK).  Three measurements were taken, and the mean of the measurements were 133 
calculated.  A venous blood sample was then collected into a lithium-heparin tube and 134 
centrifuged at 4,000 rpm at 4°C for 10 min, within 2 min of collection.  Lithium-heparin 135 
plasma was subsequently extracted and immediately frozen at -80°C for later analysis of 136 
[NO2-] in duplicate via ozone-based chemiluminescence 29. 137 
 138 
Participants were then provided with standardised breakfast.  Descriptive measures and a 139 
Physical Activity Level of 1.7 was used to calculate the participant’s individual resting 140 
energy expenditure (Schofield Equation, 1985).  This subsequently identified the amount of 141 
cereal (Rice Snaps, Tesco, Manchester, UK) and semi-skimmed milk (1g/kg/bm) each 142 
individual needed to consume to meet 10% of their daily energy requirements.  This 143 
standardised fixed-energy breakfast meal consisted of a cereal: milk ratio of 30 g: 120 ml and 144 
delivered fat, protein and carbohydrate with a macronutrient composition of 14, 14 and 72%, 145 
respectively 30.  One-hour post breakfast consumption, participants received the intervention 146 
drink.  Ninety minutes after ingestion of the supplement, vascular measures were reassessed 147 
and participants completed one of the two cycle tests described below, as published 148 
pharmacokinetic data have shown that this time frame should coincide with peak plasma 149 
concentrations of phenolic acids following MC supplementation 9,11. 150 
 151 
The exercise protocol consisted of three “step” exercise tests including two moderate 152 
intensity step tests followed by one severe-intensity exercise bout.  All participants performed 153 
a total of four bouts of moderate intensity exercise and two bouts of severe-intensity exercise 154 
for each experimental condition; this protocol replicated previously work 30.  Each transition 155 
began with 3 min of baseline cycling at 20 W before an abrupt transition to the target work 156 
rate.  Each moderate intensity bout lasted 6 min.  A passive recovery of 5 min separated the 157 
transitions.  On two of the study visits (one occasion for each supplement), participants 158 
cycled for 6 min at a severe-intensity constant work rate (70% Δ), followed immediately by a 159 
60 s all-out sprint at maximum effort.  The resistance on the pedals during this sprint was set 160 
using the linear mode of the Lode ergometer, so that each participant would attain the power 161 
output calculated to be 50% Δ when considering the participants preferred cadence (linear 162 
factor = power/preferred cadence2).  Participants were provided with a 5 s countdown prior to 163 
the sprint.  On the other two study visits (one occasion for each supplement), the severe-164 
intensity constant-work-rate bout was continued to the limit of tolerance. The time to task 165 
failure was used as a measure of exercise tolerance and was immediately recorded when the 166 
pedal rate fell by > 10 rpm below the required pedal rate. 167 
Treatments and dietary control 168 
Participants consumed either 60 ml of commercially available MC concentrate 169 
(CherryActive®, Hanworth, UK) or fruit-flavoured cordial in a double-blind, cross-over 170 
manner.  The choice to use 60 ml was based on previous work that showed a greater uptake 171 
of anthocyanin and phenolic acids in vivo post-consumption when compared to a 30 ml dose 172 
3,9,11.  The concentrate was diluted with 100 ml of water prior to consumption.  The PLA 173 
supplement consisted of a commercially available, low fruit (<1%) cordial (Kia Ora, Coca 174 
Cola Enterprises, Uxbridge, UK) cordial mixed with water, whey protein isolate (Arla Foods 175 
Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK), to match the MC 176 
concentrate for volume and macronutrient content (Energy = 204 kcal, volume = 60 ml, 177 
carbohydrates = 49 g, protein = 2.2 g and fat = 0 g). 178 
 179 
Prior to study commencement, it was explained to participants that the aim of the study was 180 
to investigate the effect of a fruit juice on vascular function.  As a result, they were unaware 181 
which beverage was the experimental drink. There were no adverse events reported in 182 
response to the intervention products. Subjects consumed all doses of the supplement for each 183 
experimental condition, and all participants complied with the low-polyphenolic experimental 184 
diet according to the food diaries. 185 
Measurements  186 
During all tests, pulmonary gas exchange and ventilation were measured breath-by-breath.  187 
Participants wore a nose clip and breathed through a low-dead-space, low-resistance 188 
mouthpiece-and-impeller turbine assembly. Following calibration according to 189 
manufacturer’s recommendations, the inspired and expired gas volume was continuously 190 
sampled at 100 Hz; gas concentration signals were continuously sampled at 100 Hz using 191 
paramagnetic (O2) and infrared (CO2) analyzers (Oxycon, Care Fusion, Rolle, Switzerland). 192 
For data analysis, the moderate bouts of exercise were exported in 10-s averages and then 193 
averaged for all bouts.  End-exercise V̇O2 (average over the last 30 s and 60 s of the bout), 194 
baseline V̇O2 (average over the 60 s prior to exercise) and the amplitude (the difference 195 
between the end-exercise and baseline V̇O2) were analysed.  For the severe bouts of exercise, 196 
the data were exported in 10-s averages and then all bouts were averaged.  Baseline V̇O2 197 
(average over the 60 s prior to exercise), the V̇O2 at 120 s (the average from 110 s to 130 i.e. 198 
120 s +/- 10 s) and the end-exercise V̇O2 (the average over the last 30 s of the bout) were 199 
identified. The peak V̇O2 was identified using the end- exercise V̇O2. Furthermore, the 200 
difference between the baseline and 120 s V̇O2 provides a surrogate for the fundamental 201 
amplitude whilst the difference between V̇O2 at 120 s and end-exercise (exhaustion) was used 202 
as a surrogate of the V̇O2 slow component. 203 
The oxygenation status of the vastus lateralis of the right leg was monitored near-infrared 204 
spectroscopy system (NIRS; INVOS 5100C, Somanetics, Troy, MI, USA) at two different 205 
wavelengths (765 nm and 855 nm). The intensity of the transmitted light was continuously 206 
recorded at 1 Hz. Based on the absorption and scattering coefficients of light at each 207 
wavelength, determined by Beer–Lambert Law, concentrations were estimated for oxy 208 
(HbO2), deoxy (HHb), and total haemoglobin.   The leg was initially cleaned around the belly 209 
of the muscle, and the optodes were placed 20 cm above the fibular head.  The probes were 210 
secured to the skin surface and covered with an elasticized, tensor bandage to minimize the 211 
influence of extraneous light, and to avoid movement of the probe relative to the skin, while 212 
allowing unrestricted movement.  The NIRS data were acquired continuously throughout the 213 
exercise protocol and output every 5 s and recorded for later offline analysis.  The NIRS data 214 
output was time stamped at the start of each task segment to assure that data corresponded to 215 
the relevant period of task performance. To provide information on muscle oxygenation, 216 
NIRS data was averaged at the time points of interest and relative concentration changes in 217 
HbO2 and HHb were calculated.  218 
The tissue oxygenation index (TOI) was calculated using the following equation 30 219 
TOI =    [HbO2]  220 
 [HbO2] + [HHb] × 100                 Equation 1 221 
Pulse wave velocity (PWV) and pulse wave analysis (PWA) were determined by using 222 
Arterial Tonometry (SphygmoCor CPV system, ScanMed Medical, UK).  The aortic pulse 223 
waveform and augmentation index were derived at the radial artery and PWV was 224 
determined between carotid and femoral sites.  A pencil-type probe was used for all 225 
measurements and was held at the base of the neck over the carotid artery and at the inguinal 226 
crease over the right femoral artery.  Recordings were taken when a reproducible signal was 227 
obtained with a high amplitude excursion.  The distance between carotid and femoral sites 228 
was measured and electrocardiogram gating permitted the time lapse between pulse waves at 229 
the carotid and femoral sites to be calculated. Inter- and intra-trial % coefficient of variation 230 
(CV) for this method was 3.3 and 3.1%, respectively. 231 
During the exercise trials, a blood sample was collected from a fingertip into a capillary tube 232 
at baseline, over the 20 s preceding the step transition in work rate, the 20 s preceding the 233 
completion of 360 s of moderate- and severe-intensity cycling exercise, immediately 234 
following the 60-s all-out sprint and immediately after exhaustion during the severe-intensity 235 
constant-work-rate trial.  These whole blood samples were analysed to determine blood 236 
lactate (Biosen C_Line, EKF Diagnostic, Barleben, Germany).  Intra-sample coefficient of 237 
variation for this instrument was 1.8%. 238 
Plasma [nitrate] and [nitrite] determination 239 
All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO 240 
intermediates prior to [NO2-] and [NO3-] analysis.  Plasma samples were deproteinized using 241 
zinc sulfate/sodium hydroxide precipitation prior to determination of [NO3-]. Firstly, 500 μL 242 
of 0.18 N NaOH was added to 100 µL of sample followed by 5 min incubation at room 243 
temperature.  Subsequently, samples were treated with 300 μL aqueous ZnSO4 (5% w/v) and 244 
vortexed for 30 s before undergoing an additional 10 min incubation period at room 245 
temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was 246 
removed for subsequent analysis.  The [NO3-] of the deproteinized plasma sample was 247 
determined by its reduction to NO in the presence of 0.8 % (w/v) VCl3 in 1 M HCl within an 248 
air-tight purging vessel.  Plasma samples were introduced to the vessel via 50 µL injections 249 
into the septum at the top of the vessel.  The spectral emission of electronically excited 250 
nitrogen dioxide, derived from the reaction of NO with ozone, was detected by a 251 
thermoelectrically cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase 252 
chemiluminescence nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK). 253 
The [NO3-] was determined by plotting signal (mV) area against a calibration plot of sodium 254 
nitrate standards.  The [NO2-] of the undiluted (non-deproteinized) plasma was determined by 255 
its reduction to NO in the presence of glacial acetic acid and aqueous NaI (4% w/v) from 256 
sodium nitrite standards.  100 µL injections were used for plasma [NO2-] determination.   257 
Statistical Analysis 258 
Statistical analysis was performed using PASW Statistics 21.0 for Windows (SPSS, Inc., 259 
Chicago, IL.).  All group characteristics were reported as means ± standard deviations, unless 260 
otherwise stated.  A 2 (MC vs. PLA) × 2 (pre vs. post) repeated measures analysis of variance 261 
(ANOVA) was employed to assess between–intervention differences in V̇O2, NIRS–TOI, 262 
blood pressure, arterial stiffness and lactate. Mauchly’s Test of Sphericity was used to check 263 
homogeneity of variance for all ANOVA analyses and where necessary, violations of the 264 
assumption were corrected using the Greenhouse–Geisser adjustment. Significant main 265 
effects were followed up using LSD post hoc analysis.  Exercise performance and NO2− and 266 
NO3- were analysed using a paired samples t-test. Statistical significance was accepted when 267 
P < 0.05. 268 
Results  269 
Eleven physically active males volunteered to take part in the study, but one participant 270 
voluntarily withdrew after the second study day (n=10).   271 
Pulmonary V̇O2 kinetics 272 
The pulmonary V̇O2 data for the moderate- and severe-intensity cycle tests are reported in 273 
Table 1.  There were no significant between-supplement differences for the baseline and end-274 
exercise V̇O2 during the moderate-intensity step exercise tests (P > 0.05).  Accordingly, the 275 
fundamental V̇O2 amplitude was not significantly different between the conditions (0.55 ± 276 
0.09 and 0.60 ± 0.07 l/min with MC concentrate and PLA respectively, P > 0.05). 277 
 278 
The baseline and end-exercise V̇O2 during severe-intensity exercise were not significantly 279 
impacted by the dietary interventions employed in this investigation (P > 0.05 for all 280 
comparisons).  The V̇O2 at exhaustion was not significantly different between experimental 281 
conditions and was also not significantly different from the V̇O2peak attained in the ramp 282 
incremental test (P > 0.05).  No significant differences were reported between MC and PLA 283 
in V̇O2 amplitudes from baseline to 120 s of exercise.  No differences in V̇O2 slow component 284 
were observed across the experimental conditions (Table 1). There were no differences in 285 
V̇CO2 between the conditions during moderate- or severe-intensity cycle exercise (P > 0.05 286 
for all comparisons). 287 
 288 
     >>>> Table 1 <<<< 289 
Exercise performance  290 
The time to exhaustion during the severe-intensity constant-work-rate cycle trials (the 291 
exercise tolerance test) are presented in Fig 1; while the power profiles for the two 292 
experimental conditions during the 60-s all-out sprint that followed the 6-min bout of severe 293 
intensity exercise (the exercise performance test) are presented in Fig 2.  There were no 294 
significant differences in time to exhaustion during the exercise tolerance test between the 295 
MC (772 ± 34 s) and the PLA conditions (733 ± 34 s, P = 0.323).  A significant main effect 296 
for supplement was observed for the peak power over the first 20 s and total work completed 297 
during the 60-s all-out sprint that followed the 6 min severe intensity preload (P < 0.002).  298 
Follow-up analyses demonstrated that, compared with PLA, MC concentrate supplementation 299 
increased the test peak power by 9.5% (363 ± 42 vs. 330 ± 26 W, P = 0.034; Fig 2) and the 300 
total work completed during the 60 s sprint by 10% between conditions (21 ± 3 vs. 19 ± 3 kJ, 301 
P = 0.021).  302 
 303 
     >>>> Figure 1 <<<< 304 
     >>>> Figure 2 <<<< 305 
 306 
NIRS  307 
The tissue oxygenation index data during moderate- and severe-intensity cycle exercise with 308 
PLA and MC supplementation are reported in Table 2.  There were no significant differences 309 
between the experimental conditions during the moderate or severe-intensity exercise (P > 310 
0.05).   311 
     >>>> Table 2 <<<< 312 
 313 
Vascular measures 314 
There was a significant interaction effect for supplement on SBP (P < 0.05), with follow-up 315 
analyses showing that SBP was lower 1.5 h post MC supplementation, with reductions of 5 ± 316 
2 mmHg compared to the placebo trial.  No other vascular variables (DBP, mean arterial 317 
pressure (MAP), PWV, augmentation index (AIx) and AIx corrected for HR at 75 bpm) were 318 
altered after consumption of the MC concentrate compared to the placebo treatment.  The 319 
absolute values for all variables are presented in Table 3. 320 
 321 
  322 
     >>>>Table 3<<<< 323 
 324 
Plasma [NO2−] and [NO3−] 325 
Due to sampling error, blood was analysed in 8 participants.  The plasma [NO2−] and [NO3−] 326 
for the MC and PLA conditions are reported in Table 4.  There were no changes for NO2− or 327 
NO3− in the MC supplemented trial when compared to the placebo (P > 0.05). 328 
 329 
     >>>> Table 4<<<< 330 
 331 
Lactate  332 
There was no treatment or treatment × time interaction effect observed in blood [lactate], 333 
however there was a significant time effect identified during both the exercise performance 334 
and tolerance test (P < 0.001).   No other differences were reported.  Absolute values are 335 
presented in Table 5.   336 
     >>>> Table 5<<<< 337 
 338 
  339 
Discussion 340 
The principal novel findings from this study are that, compared with an energy-matched 341 
placebo, acute MC supplementation enhanced end-sprint performance following a 6 min 342 
severe-intensity preload in trained cyclists without changing V̇O2, plasma [NO2-] or muscle 343 
oxygenation variables. In addition, SBP was lower 1.5 h post MC consumption but not with 344 
PLA.  345 
Influence of MC supplementation on performance  346 
In the current study, peak power output and total work done during a 60-s sprint increased by 347 
9.5 and 10%, following MC relative to the PLA supplementation.  While tart cherry 348 
supplementation has been shown to improve exercise recovery 23,24 and decrease markers of 349 
inflammation and oxidative stress 1,3, studies investigating the effects of tart cherries on 350 
exercise performance are limited and equivocal.  Of the two studies investigating the 351 
influence of MC supplementation on exercise performance to date, one reported improved 352 
performance in males completing a half marathon (21.1km) run, as evidenced by a faster 353 
overall race pace compared to the PLA group 19. However, as previously mentioned, there 354 
were some limitations to the study design and therefore these results should be interpreted 355 
with a degree of caution.  While Levers et al.19 designed an experiment to assess the influence 356 
of ingesting 480 mg of powdered tart cherries for 10-days, including supplementation on race 357 
day up to 48-hr post-run, we investigated the effects of a single dose (60 ml) of MC 358 
concentrate on exercise performance using a cross over study design.  Despite the differences 359 
in dosing strategies, both studies reported improvements in performance.  Therefore, our 360 
findings suggest that acute as well as chronic supplementation with MC concentrate has the 361 
potential to improve performance, specifially end-sprint performance. Conversely, an earlier 362 
study by Clifford and colleagues 18 reported no difference in time trial performance in 363 
moderately-trained individuals following the ingestion of 200 mg of powdered tart cherries 364 
for 3-days.  These conflicting findings might be due to the differences in dosing procedures 365 
(480mg versus 200mg) and exercise tests performed (20 km cycling time trial versus half 366 
marathon).  The current investigation used a MC concentrate as opposed to the powdered 367 
capsules used in both previous studies.  The MC concentrate was found to contain 73.50 368 
±0.20 mg cyanidin-3-glucoside /L and 178.75 ± 0.87 mean gallic acid equiv/L 11. The 369 
exercise protocol used in the current study also differed to the two previous studies.  370 
 There were no differences observed for time to exhaustion between the MC and the PLA 371 
trial in the current study.  Trinity and colleagues also reported that polyphenol 372 
supplementation did not improve performance during prolonged exhaustive exercise (one 373 
hour of exercise including a 10 min time trial) or during shorter duration high intensity 374 
exercise (time to fatigue at VO2max).  There remains a debate surrounding the applicability 375 
and repeatability of the time to exhaustion test as there is a larger day to day variability when 376 
compared to a time-trial 32.  However, a recent addition to the literature concluded that a time 377 
to exhaustion test is regarded as a more useful measure of cycling performance compared to a 378 
time trial 33.   379 
There were no changes in V̇O2, blood [lactate] or muscle oxygenation in the current study 380 
suggesting that the ergogenic effects of MC supplementation were not linked to improved 381 
metabolic responses or better matching of muscle O2 supply to O2 demand. Furthermore, 382 
plasma [NO2-] was not different between the two trials and since plasma [NO2-] is a sensitive 383 
biomarker of eNOS activity 26, the performance improvements with MC supplementation 384 
appear to be independent of NO-mediated signalling.  It is more likely that the enhanced 385 
performance might be mediated through the AOX and vasodilatory properties of polyphenol-386 
rich MC.  When undertaking high intensity exercise, ROS are produced causing cellular 387 
damage and oxidative stress 34. AOX have the ability to prevent or reduce the extent of 388 
oxidative damage to other molecules.  It is therefore possible that the AOX effects of MC 389 
concentrate were only significant when skeletal muscle contractions were most likely to be 390 
compromised by increased oxidative stress 34.  In agreement, an investigation by MacRae and 391 
Mefferd 35 reported that the addition of a flavonoid quercetin to a liquid AOX supplement 392 
significantly enhanced the AOX effect of the supplement and resulted in a 3.1% performance 393 
improvement during a 30 km cycle time trial.  Hence, it is possible that a combination of 394 
AOX compounds may induce larger effects on exercise performance.  It is also possible that 395 
this increase in AOX defence from the MC concentrate relative to the PLA may have been 396 
amplified by the lowering of dietary sources high in AOX’s i.e. dietary restrictions imposed 397 
on participants. Previous literature has reported that the baseline antioxidant profile of an 398 
individual is an important determinant of the ergogenic effectiveness of an antioxidant 399 
treatment 36.  400 
Given that MC concentrate has been shown to possess numerous AOX and polyphenolic 401 
compounds 1,2, it seems reasonable that the improvement in exercise performance in the 402 
current study might be as a result of these AOX compounds. It is worth noting that MC 403 
supplementation could have prolonged the duration for which the participants were in the 404 
optimal cellular redox state for force production 37 such that when they were required to 405 
produce an all-out sprint, they produced a higher peak power and completed more work.  In 406 
addition, muscle blood flow is considered an important limiting factor during high intensity 407 
exercise 38, and it is possible that the improvement in exercise performance might be linked, 408 
in part, to an increase in blood flow. Previous research has demonstrated the vasodilatory 409 
effects associated with anthocyanin intake 39 and more recently, MC supplementation has 410 
been shown to alter vascular function and behaviour 9,10,11 .   411 
Influence of MC supplementation on plasma [NO2−] 412 
Nitric oxide is a key regulator of vascular integrity.  This multifaceted physiological 413 
signalling molecule can be synthesized endogenously through NOS with plasma [NO2-] 414 
reflecting NOS activity 26.  No significant difference in plasma [NO2-] was reported between 415 
the MC and PLA trials in the current study.  This is somewhat in agreement with the findings 416 
from Keane and colleagues 11, where no main effect for plasma NO3- or NO2- was observed 417 
following 60 mL MC supplementation using an ELISA kit.  Importantly, the lack of a change 418 
in plasma [NO2-] in the current study extends our previous findings by using a more sensitive 419 
method to detect plasma [NO2-] in the nM range and this better reflects NOS activity than 420 
plasma [NO3-] 26.  Since trained endurance cyclists were recruited in the current study, and 421 
since endurance training increase NOS expression 40, it is likely that eNOS-derived NO 422 
production was already optimal in this cohort and therefore no changes were observed after 423 
MC supplementation.  It is also noteworthy that the resting plasma [NO2-] was relatively low 424 
in the current study when compared with previous literature 31. This could be as a result of the 425 
dietary restrictions imposed on the participants on the day preceding the trial and/or a low 426 
intake of nitrate-rich foods in the period leading into the trials. 427 
Influence of MC supplementation on blood pressure  428 
A primary outcome of enhanced NO synthesis is a reduction in blood pressure owing to NO-429 
induced smooth muscle relaxation 41.  The current study reported a significant reduction in 430 
SBP 1.5 h post MC ingestion relative to placebo, however this augmented modulation 431 
occurred in the absence of changes in NO biomarkers.  These results are consistent with a 432 
recent study demonstrating that supplementation with the NOS substrate, L-Citrulline 31, 433 
lowered blood pressure in the absence of a change in plasma [NO2-].  Mechanistically, it 434 
would appear that the lowering of BP with acute MC supplementation in the current study is 435 
largely NO-independent and is more likely to be a function of the increase in circulating 436 
phenolic metabolites post MC ingestion 11. There was no change in arterial stiffness observed 437 
in the current study.  This observation is in line with previous studies reporting improved 438 
SBP following MC consumption in males with early hypertension 11 and middle aged adults 439 
10, with no improvement in arterial stiffness.   It has previously been reported that concurrent 440 
improvements in all measures of vascular function are not always observed 11. Further 441 
research is required to investigate the mechanisms by which MC supplementation might 442 
positively affect vascular and other physiological responses. 443 
A limitation of the current study is the lack of polyphenol analysis and oxidative stress 444 
biomarkers. Conceivably, there are a number of mechanisms that could contribute to the 445 
physiological effects exerted by MC, and further research is needed to address the underlying 446 
mechanisms for these observations.  In addition, participants in the current study were asked 447 
to adhere to strict dietary guidelines in the days preceding the trials and future work should 448 
attempt to investigate the potential synergetic effects of MC supplementation within habitual 449 
dietary practices.   450 
In conclusion, this study has shown that acute supplementation with MC juice can lower 451 
blood pressure and improve exercise performance, specifically end-sprint performance, in 452 
trained endurance cyclists.  There were no changes in plasma [NO2-], pulmonary V̇O2, or 453 
muscle oxygenation after ingesting tart cherry juice so the improvements in blood pressure 454 
and exercise performance in this study might be mediated through the potent antioxidant 455 
properties of MC juice.  The results of this study suggest that supplementation with MC 456 
concentrate might represent, a practical, non-pharmacological, dietary intervention to reduce 457 
blood pressure and enhance end-sprint performance in trained individuals.  458 
Perspectives 459 
The improvement in end-sprint performance in the current study could prove advantageous in 460 
sporting situations where very little separates opponents.  After completing exercise that was 461 
deemed metabolically strenuous, participants performed better over a 60-s sprint when 462 
supplemented with MC compared to placebo. Consequently, MC supplementation might be 463 
of interest to athletes, coaches and applied sport scientists.  Also, the marked reduction in 464 
systolic blood pressure we observed with MC supports previous studies 10,11 and underlines 465 
the potential importance of MC as an adjunct to the management of hypertension.   466 
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